Search Results

GPCR Podcast, Ben, a postdoctoral fellow at the University of Michigan, walks us through how positive Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase That’s huge.” – Ben Clements By combining chronic pain models with receptor-level pharmacology, Ben Ben’s approach injects new life into an area most clinicians have given up on. The GPCR Angle Ben sees GPCRs as untapped goldmines for drug discovery.

Ben Myers!

They know how many months of runway remain, but not which strategic options are already gone . but by fear of cash burn 4️⃣ Fundraising becomes the main plan instead of one option among several None Not because the money is gone, but because the company no longer has the freedom to pursue its best options

<< Back to podcast list Strategic Partner(s) Murat Tunaboylu & Ben Holland About Murat Tunaboylu "Murat GPCR About Ben Holland "Ben gained his masters in Engineering Science from Oxford, taking a specialisation nearly 10 years, applying it to antibody generation, analysis, and property prediction since 2017" Ben

GPCR scientist Ben Clements shares how positive allosteric modulators could transform opioid therapy From Aspirations to Application: Ben’s Path into Science Ben shares his winding yet deliberate entry Allosteric Modulation: The New Frontier of GPCR Drug Discovery Ben reflects on the emerging potential We produce great data, but we also joke around. That’s how we work best.” About Ben Clements Dr.

Benjamin Myers Ben Myers is an assistant professor at the University of Utah School of Medicine in Salt Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic More recently, Ben’s lab has begun studying GPCR signaling pathways that operate within the primary cilium Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford Prior to that, Ben received his Ph.D. from UCSF in 2008, where he worked with David Julius on the structure